7月24日，民银资本盘中下跌13.16%，报3.22港元/股，成交额3374.05万港元。该股自7月21日以来持续大幅走低，保荐项目普祺医药IPO招股书失效引发的负面影响仍在发酵。
消息面上，普祺医药港股招股书于7月21日正式失效，民银资本为联席保荐人之一。此前公司年度净利润同比增长197.73%至1.51亿港元，主因证券承销及保荐费收入大幅增加，保荐项目未能推进令市场对其核心业务收入持续性产生担忧。该股7月22日曾出现超跌反弹但未能延续，此后连续回落，短期抛压依然较重。此外，公司总经理李明因控股股东内部工作调动已于近期退任，管理层变动亦增添不确定性。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.